[Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
Recombinant interferon alpha-2 (Sch 30500) was administered to 29 patients with advanced gynecological cancers (14 patients with cancer of the cervix, 8 with ovarian cancer, 4 with uterine sarcoma, 2 with endometrial cancer and 1 with unclassified cancer). No antitumor effects (CR and PR) were noted in 23 evaluable patients. Side effects observed were fever, tachycardia, diarrhea, chills, general fatigue, anorexia, nausea and vomiting. In some patients, leukopenia, decrease of hemoglobin and elevation of SGOT and SGPT were observed. No production of antibody for Sch 30500 was noted.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007890:Leiomyosarcoma / Q000628:therapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*; D013610:Tachycardia / Q000209:etiology; D002583:Uterine Cervical Neoplasms / Q000628:therapy; D014594:Uterine Neoplasms / Q000628:therapy*
D007370:Interferon Type I